At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company’s inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.
Company Growth (employees)
Rockville, US
Size (employees)
42 (est)+11%
GlycoMimetics was founded in 2003 and is headquartered in Rockville, US

Key People at GlycoMimetics

Brian Hahn

Brian Hahn

Chief Financial Officer
John J. Baldwin

John J. Baldwin

Michael Henos

Michael Henos

Franklin H. Top

Franklin H. Top

William Gust

William Gust

M. James Barrett

M. James Barrett

Chairman of the Board of Directors

GlycoMimetics Office Locations

GlycoMimetics has office in Rockville
Rockville, US

GlycoMimetics Metrics

GlycoMimetics Summary

Market capitalization

$147.7 m

Closing share price

GlycoMimetics's current market capitalization is $147.7 m.

GlycoMimetics Financials

GlycoMimetics's revenue is $15 m in FY, 2014 which is a 25.1% decrease from the previous period.
FY, 2014FY, 2015FY, 2016


$15 m$20.1 m$18.5 k

Revenue growth, %


Operating expense total

$26.2 m$32.9 m


($11.1 m)($12.8 m)

Net Income

($11.1 m)($12.8 m)($31.8 m)

Operating cash flow

$52.9 m($8.4 m)

GlycoMimetics Market Value History

We estimate that GlycoMimetics's current employees are approximately 26% female and 74% male.

GlycoMimetics Company Life

You may also be interested in